Last week, BioBuzz hosted the second event in our BioInnovation series, centered on rare diseases. The event was a sell-out, with 160 attendees and an impressive 60%+ representation from biotech and pharma. We’re thrilled with the momentum and can’t wait for our upcoming AI x Bio event on April 9th!
Philadelphia’s Proscia: Raises $50M to Advance AI-Driven Technology More
Roche: settles UPenn suit alleging patent infringement by Herceptin, 3 other breast cancer meds More
Clario: announces acquisition of imaging provider NeuroRx More
BioLabs: Expands and Rebrands Philadelphia Location as BioLabs for Advanced Therapeutics More
Marengo Therapeutics: Enters Multi-Year Collaboration With University of Pennsylvania Institute for Immunology and Immune Health to Advance Next Wave Precision T Cell Immunology Research in Oncology and Autoimmune Diseases More
Paratek Pharmaceuticals: Will Acquire Optinose, Creating Significant Commercial Expansion Opportunities for XHANCE in Chronic Rhinosinusitis (CRS) More
Lungpacer Medical: will nearly double workforce to support first product launch More
CLINICAL & COMMERCIAL
iECURE: Presentation of Full Data for the First Infant Dosed With ECUR-506 in OTC-HOPE Phase 1/2 Clinical Trial at the 2025 ACMG Annual Clinical Genetics Meeting More
BriaCell: Second Data Safety Monitoring Board Issues Positive Recommendation to Continue Phase 3 Study in Metastatic Breast Cancer More
Incyte: Positive Topline Results From Two Phase 3 Clinical Trials of Povorcitinib in Patients With Hidradenitis Suppurativa More
ANI Pharmaceuticals: Launch of Nitazoxanide Tablets More
Ocugen: Data and Safety Monitoring Board Reviews Cohort 1 Safety Data and Approves Dosing Cohort 2 in the Clinical Trial of OCU200—a Novel Fusion Protein for Diabetic Macular Edema More
Maxona Pharmaceuticals: MAX-001 Phase 1 Clinical Program Results More
Virpax: Receives Positive Probudur™ Results for Dose Range Study Moves Towards Next Steps in IND More
WORKFORCE
CLEU Diagnostics: Former Alere and LumiraDx R&D Chief Nigel Lindner Joins to Launch Revolutionary LabSimple Diagnostic Platform More
The Wistar Institute: Appoints welcomes Charles B. Cairns, M.D., Catherine Creese, and Carolyn Magill to the Board of Trustees More
Here are some other innovative companies in the region that are hiring:
Harmony Biosciences (Plymouth Meeting, PA) – A leading pharma company dedicated to innovative therapies for patients with rare neurological diseases. Check out jobs here>
Director, Medical Writing
Senior Director, Clinical Pharmacology
Senior Director, Business Development
Context Therapeutics (Philadelphia, PA) – A biopharma company advancing T cell engaging bispecific antibodies for solid tumors. Check out jobs here>
Head of Regulatory
Senior Director/VP, Data management
Director/Senior Director, Project Management
Cabaletta Bio (Philadelphia, PA) – A clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies here>
Director, Clinical Program Management
Director, Clinical Scientist
Senior Director, CMC Regulatory Affairs
VintaBio (Philadelphia, PA) – Viral Vector Manufacturing. Check out jobs here>
Head of Analytical Development & Quality Control
Quality Assurance Document Control Training Manager
Office Manager
Century Therapeutics (Philadelphia, PA) – Century Therapeutics is an innovative biotechnology company that is building an industry leading allogeneic iPSC-derived cell therapy platform. Check out jobs here>
Scientific Director, Upstream Process
Senior Director, Clinical Development
CMMS Specialist
BUZZIN’ EVENT
Keep an eye out for the next event!
BioInnovation Series Event Philadelphia’s Push: Breaking Barriers in Rare Disease Research
Philadelphia is emerging as a national leader in rare disease research, and the latest BioBuzz BioInnovation Series event on March 18th highlighted this growing momentum. Hosted at Quorum at uCity Square, the event brought together over 150 attendees, including scientists, biotech leaders, and patient advocates, all focused on tackling the challenges that hinder progress in rare disease treatments. Co-organized with Wexford Science + Technology and uCity Square, the event fostered meaningful discussions on how to drive innovation and collaboration in this critical area of medicine.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.
